Wells Fargo
VYGR icon

Wells Fargo’s Voyager Therapeutics VYGR Stock Holding History

Wells Fargo’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Buy
125,042
+23,320
+23% +$88.4K ﹤0.01% 4718
2026
Q1 		$393K Sell
101,722
-30,941
-23% -$122K ﹤0.01% 4295
2025
Q4 		$521K Buy
132,663
+27,964
+27% +$124K ﹤0.01% 4460
2025
Q3 		$489K Buy
104,699
+45,428
+77% +$164K ﹤0.01% 4317
2025
Q2 		$184K Buy
59,271
+2,900
+5% +$9.35K ﹤0.01% 4818
2025
Q1 		$191K Sell
56,371
-10,347
-16% -$48.3K ﹤0.01% 4741
2024
Q4 		$378K Buy
66,718
+2,400
+4% +$15.5K ﹤0.01% 4370
2024
Q3 		$376K Buy
64,318
+298
+0.5% +$2.17K ﹤0.01% 4178
2024
Q2 		$506K Buy
64,020
+6,280
+11% +$52.6K ﹤0.01% 3905
2024
Q1 		$538K Buy
57,740
+48,025
+494% +$405K ﹤0.01% 3837
2023
Q4 		$82K Buy
9,715
+1,873
+24% +$13.6K ﹤0.01% 5026
2023
Q3 		$60.8K Sell
7,842
-7,120
-48% -$65K ﹤0.01% 5075
2023
Q2 		$171K Buy
14,962
+12,896
+624% +$133K ﹤0.01% 4685
2023
Q1 		$15.9K Buy
2,066
+3
+0.1% +$24 ﹤0.01% 5717
2022
Q4 		$12.6K Sell
2,063
-261
-11% -$1.48K ﹤0.01% 5459
2022
Q3 		$13K Sell
2,324
-2,591
-53% -$16.6K ﹤0.01% 5591
2022
Q2 		$29K Sell
4,915
-683
-12% -$4.61K ﹤0.01% 5278
2022
Q1 		$42K Sell
5,598
-27,986
-83% -$125K ﹤0.01% 5739
2021
Q4 		$91K Sell
33,584
-22,899
-41% -$78.1K ﹤0.01% 5694
2021
Q3 		$148K Sell
56,483
-43,760
-44% -$142K ﹤0.01% 5222
2021
Q2 		$414K Buy
100,243
+21,887
+28% +$99.2K ﹤0.01% 4718
2021
Q1 		$369K Sell
78,356
-62,361
-44% -$425K ﹤0.01% 4856
2020
Q4 		$1.01M Sell
140,717
-292,847
-68% -$2.82M ﹤0.01% 4018
2020
Q3 		$4.63M Sell
433,564
-30,465
-7% -$358K ﹤0.01% 2586
2020
Q2 		$5.86M Buy
464,029
+6,123
+1% +$71.2K ﹤0.01% 2325
2020
Q1 		$4.19M Buy
457,906
+69,335
+18% +$796K ﹤0.01% 2381
2019
Q4 		$5.42M Buy
388,571
+29,178
+8% +$424K ﹤0.01% 2492
2019
Q3 		$6.18M Buy
359,393
+19,594
+6% +$411K ﹤0.01% 2364
2019
Q2 		$9.25M Sell
339,799
-22,134
-6% -$506K ﹤0.01% 2023
2019
Q1 		$6.93M Sell
361,933
-38,926
-10% -$507K ﹤0.01% 2240
2018
Q4 		$3.77M Sell
400,859
-133,228
-25% -$1.71M ﹤0.01% 2719
2018
Q3 		$10.1M Buy
534,087
+83,607
+19% +$1.6M ﹤0.01% 2062
2018
Q2 		$8.8M Buy
450,480
+59,497
+15% +$1.18M ﹤0.01% 2178
2018
Q1 		$7.35M Sell
390,983
-58,542
-13% -$1.27M ﹤0.01% 2290
2017
Q4 		$7.46M Buy
449,525
+72,335
+19% +$1.24M ﹤0.01% 2228
2017
Q3 		$7.77M Buy
377,190
+285,806
+313% +$3.23M ﹤0.01% 2162
2017
Q2 		$819K Buy
91,384
+7,807
+9% +$78.6K ﹤0.01% 3882
2017
Q1 		$1.11M Buy
83,577
+44,599
+114% +$541K ﹤0.01% 3671
2016
Q4 		$496K Buy
38,978
+13,283
+52% +$171K ﹤0.01% 4208
2016
Q3 		$309K Buy
25,695
+7,539
+42% +$102K ﹤0.01% 4236
2016
Q2 		$199K Buy
18,156
+16,500
+996% +$202K ﹤0.01% 4418
2016
Q1 		$14K Sell
1,656
-2,784
-63% -$31.6K ﹤0.01% 5598
2015
Q4 		$97K Buy
+4,440
New +$102K ﹤0.01% 4918

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wells Fargo's VYGR Position: Q2 2026 in Review

Wells Fargo increased its Voyager Therapeutics (VYGR) stake by 23% in Q2 2026, buying an estimated $88.4K and bringing the position to 125,042 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #4718.

Wells Fargo first reported a position in VYGR in Q4 2015 and has held it in 43 quarters since. The position peaked at $10.1M in Q3 2018. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Wells Fargo held 125,042 shares of Voyager Therapeutics worth $438K as of Q2 2026.
  • Wells Fargo bought 23,320 Voyager Therapeutics shares in Q2 2026, an estimated $88.4K.
  • Voyager Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4718 holding.
  • Wells Fargo first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 43 quarters since.
  • Wells Fargo's Voyager Therapeutics position peaked at $10.1M in Q3 2018.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.